Back

Targeted degradation of pathologic tau aggregates via AUTOTAC ameliorates tauopathy

Lee, J.; Kim, S. B.; Kim, H. Y.; Lee, G. E.; Lee, D. W.; Jung, E. H.; Lee, J. S.; Cho, E. H.; Park, H.-B.; Park, D.-h.; Noh, J. E.; Cha, H. S.; Oh, H. J.-y.; Lee, S. H.; Sterbenc, N.; Choi, C. Y.; Lee, M. J.; Chi, H. M.; Suh, Y. H.; Lee, K. J.; Han, D.; Sung, K. W.; Pavlin, D.; Kim, S. T.; Ji, C. H.; Pipan, M. Z.; Kwon, Y. T.

2025-09-12 neuroscience
10.1101/2025.09.10.675324 bioRxiv
Show abstract

The pathogenesis of tauopathies including Alzheimers disease (AD) and progressive supranuclear palsy (PSP) involves the misfolding and aggregation of tau. Here, we employed AUTOTAC to induce the lysosomal degradation of intraneuronal tau aggregates. ATB2005A is a 734-Da chimera that simultaneously binds {beta}-sheet-rich tau aggregates and the autophagic receptor p62/SQSTM1, leading to autophagosomal sequestration and lysosomal co-degradation. In mouse models of tauopathies, orally administered ATB2005A lowered intraneuronal tau aggregates and exerted the therapeutic efficacy in neuroinflammation as well as cognition, behavior, and muscle movements. A Phase 2 clinical trial (U34401-4/2023/14) with companion dogs carrying canine cognitive dysfunction (CCD) demonstrated the efficacy of ATB2005A, as a veterinary medicine, to reverse the disease progression. ATB2005A is under Phase 1 clinical trial with human participants in Korea (202300697). These results validate AUTOTAC as a versatile platform for developing therapeutics to eradicate toxic protein aggregates in a wide range of proteinopathies.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.